Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies999
iOnctura
iOnctura is a clinical-stage biotech developing next-generation bio-molecules for the treatment of cancer and fibrosis.
Sector
Subsector
Keywords
Location
total rounds
total raised
Proacta
Proacta Inc. is a clinical-stage biopharmaceutical company developing hypoxia-activated prodrugs for the treatment of cancer.
Sector
Subsector
Keywords
Location
total rounds
total raised
Celsion
Celsion is a biopharmaceutical company developing innovative cancer treatments.
Sector
Subsector
Location
total rounds
total raised
Speratum
Speratum is a biotechnology company that develops targeted molecular therapies for cancer treatment.
Sector
Subsector
Location
total rounds
total raised
Financials
Funding Rounds2
Number of Funding Rounds
Money Raised
Their latest funding was raised on 06.10.2017. Their latest investor Gaston Capital Partners. Their latest round Series A
Gaston Capital Partners
Gaston Capital Partners is a private equity firm in Gastonia, North Carolina.
Sector
Subsector
Keywords
Location
count Of Investments
Co-Investors
Investors1
Number of lead investors
Number of investors
Gaston Capital Partners
Gaston Capital Partners is a private equity firm in Gastonia, North Carolina.
Sector
Subsector
Keywords
Location
count Of Investments
Michael K McMahan
Michael K. (Mick) McMahan is the founder and Managing Partner of Gaston Capital Partners, LLC, a private equity firm in Gastonia, North Carolina. He has more than thirty-five years experience managing investment portfolios and working with small businesses. He has been listed as a top-ranked Charlotte-area financial advisor by the Charlotte Business Journal and in Barron's as one of the top 100 independent financial advisers in the country. He has successfully managed hundreds of millions of dollars in client assets since 1984. He is a popular public speaker who is sought after by numerous organizations to address audiences on topics such as financial investment advice, business management, and military service. Mick holds a Bachelor of Arts with Honors in Economics and a Masters in Public Administration from the University of North Carolina at Chapel Hill. He also completed the Certified Financial Planner program through the College for Financial Planning in Denver, CO; Investment Management and Asset Allocation through the Wharton Business School at the University of Pennsylvania; and Advanced Estate Planning through the Heckerling Institute at the University of Miami Law School.
current job
People
Founders2
Kevin Sill
Kevin Sill, Ph.D., is the Chief Executive Office, Chief Science Officer, President and co-founder of Intezyne. Dr. Sill completed his Ph.D. and M.S. in polymer science and engineering at the University of Massachusetts and holds a B.S. degree in chemistry from the University of Illinois. In November of 2009, Dr. Sill received the inaugural "Young Innovator of the Year" award from R&D Magazine. He is a co-inventor on 27 issued US patents as well as 61 additional international patents and has authored or co-authored 18 peer-reviewed publications in fields spanning polymer chemistry, polymer physics, nanoparticles, and drug delivery applications. Dr. Sill is a registered US Patent Agent. As a principal investigator, he has received over $2.5M in federal research funding. Dr. Sill, a recognized expert in the field of drug delivery, serves on a NIH review panel for Biomaterials, Delivery, and Nanotechnology.
current job
organization founded
Kevin Sill